盐酸西替利嗪|Cetirizine dihydrochloride |cas:83881-52-1|西域试剂

盐酸西替利嗪,Cetirizine dihydrochloride ,超级纯,99.53%

产品编号：西域试剂-17042A| CAS NO：83881-52-1| 分子式：C₂₁H₂₇Cl₃N₂O₃| 分子量：461.81

Cetirizine二盐酸盐是第二代抗组胺剂，是hydroxyzine的主要代谢产物，是外消旋的选择性H1受体反向激动剂。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
西域试剂-17042A	￥680.00	杭州北京（现货）
西域试剂-17042A	￥830.00	杭州北京（现货）
西域试剂-17042A	￥1150.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

盐酸西替利嗪

产品介绍

Cetirizine dihydrochloride 是羟嗪的羧化代谢物，是第二代抗组胺药。Cetirizine dihydrochloride 是一种特异的、口服有效的、H1 受体 的长效拮抗剂。Cetirizine dihydrochloride 标记抗过敏特性，抑制过敏反应期间嗜酸性粒细胞趋化。

生物活性

Cetirizine dihydrochloride, a second-generation antihistamine and the carboxylated metabolite of hydroxyzine, is a specific, orally active and long-acting histamine H1-receptor antagonist. Cetirizine dihydrochloride marks antiallergic properties and inhibits eosinophil chemotaxis during the allergic response.

体外研究

Cetirizine (>5 μM) at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1β. Cetirizine exerts anti-inflammatory effects beyond histamine H1-receptor antagonist^{^.}

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Human airway epithelial cell line A549.
Concentration:	0-10 μM.
Incubation Time:	24 h.
Result:	The survival of A549 cells incubated with various concentrations of cetirizine (0.1, 1, 2.5, 5, and 10 μM) for 24 hours were all higher than 90% when comparing with the control group by MTT test. Cetirizine, 5 and 10 μM, suppressed GM-CSF release by 70.71 and 61.55%, respectively. Preincubation with cetirizine, 10 μM, suppressed the IL-8 secretion by 75.04%.

体内研究
(In Vivo)

Cetirizine (20 mg/kg, mice, orally) exerts its anti-inflammatory effects by inhibiting MIF as well as IL-8 production in mice immunized and challenged with ragweed pollen^{^.}

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-week-old BALB/c mice (25-30 g) immunized and challenged with ragweed pollen^{^.}
Dosage:	2 or 20 mg/kg.
Administration:	Orally, diluted in sterile water on days 18, 19, and 20.
Result:	The neutrophilia at 8 h and eosinophilia at 24 h induced by ragweed pollen extract per os were significantly reduced in the mice treated with 20 mg/kg. The dosage with 2 mg/kg had no effect.

体内研究

Cetirizine (20 mg/kg, mice, orally) exerts its anti-inflammatory effects by inhibiting MIF as well as IL-8 production in mice immunized and challenged with ragweed pollen^{^.}

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-week-old BALB/c mice (25-30 g) immunized and challenged with ragweed pollen^{^.}
Dosage:	2 or 20 mg/kg.
Administration:	Orally, diluted in sterile water on days 18, 19, and 20.
Result:	The neutrophilia at 8 h and eosinophilia at 24 h induced by ragweed pollen extract per os were significantly reduced in the mice treated with 20 mg/kg. The dosage with 2 mg/kg had no effect.

体内研究

Cetirizine (20 mg/kg, mice, orally) exerts its anti-inflammatory effects by inhibiting MIF as well as IL-8 production in mice immunized and challenged with ragweed pollen^{^.}

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-week-old BALB/c mice (25-30 g) immunized and challenged with ragweed pollen^{^.}
Dosage:	2 or 20 mg/kg.
Administration:	Orally, diluted in sterile water on days 18, 19, and 20.
Result:	The neutrophilia at 8 h and eosinophilia at 24 h induced by ragweed pollen extract per os were significantly reduced in the mice treated with 20 mg/kg. The dosage with 2 mg/kg had no effect.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (216.54 mM; Need ultrasonic)

H₂O : 100 mg/mL (216.54 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1654 mL	10.8270 mL	21.6539 mL
5 mM	0.4331 mL	2.1654 mL	4.3308 mL
10 mM	0.2165 mL	1.0827 mL	2.1654 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 120 mg/mL (259.85 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.41 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.41 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.41 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献

. Caroline M. Spencer, et al. Cetirizine. Drugs 46 (6): 1055•1080, 1993.

. Shih MY, et al. Influence of cetirizine and levocetirizine on two cytokines secretion in human airway epithelial cells. Allergy Asthma Proc. 2008 Sep-Oct;29(5):480-5. [Content Brief]

. Shimizu T, et al. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy. 2004 Jan;34(1):103-9. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS07
信号词	Warning
危害声明	H302
警示性声明	P301 + P312 + P330
个人防护装备	dust mask type N95 (US);Eyeshields;Faceshields;Gloves
危害码 (欧洲)	Xn: Harmful;
风险声明 (欧洲)	R22
安全声明 (欧洲)	26-36
危险品运输编码	UN 3249
WGK德国	3
RTECS号	AG0977500
包装等级	III
危险类别	6.1(b)
海关编码	2933599090

1. 物质的识别

产品名：	Cetirizine Dihydrochloride
CAS号：	83881-52-1
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Cetirizine Dihydrochloride
别名：	P071; Cetirizine Di
分子式：	C21H27Cl3N2O3
分子量：	461.81

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。